Blood Disorder News and Research

RSS
Alexion Pharmaceuticals reports total revenues of $117.6M from net product sales of Soliris

Alexion Pharmaceuticals reports total revenues of $117.6M from net product sales of Soliris

Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Study provides benchmark data to evaluate quality of management of sickle cell disease

Study provides benchmark data to evaluate quality of management of sickle cell disease

Sickle cell disease: Rehospitalization rates high

Sickle cell disease: Rehospitalization rates high

Rebirth of the cursed drug Thalidomide

Rebirth of the cursed drug Thalidomide

Genetic instability in people with Fanconi anemia: New proteins in FA DNA repair pathway may help explain

Genetic instability in people with Fanconi anemia: New proteins in FA DNA repair pathway may help explain

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

TGen, Virginia G. Piper Cancer Center and Side-Out Foundation team up for breast cancer study

TGen, Virginia G. Piper Cancer Center and Side-Out Foundation team up for breast cancer study

Side-Out Foundation sponsors new advanced breast cancer clinical trial

Side-Out Foundation sponsors new advanced breast cancer clinical trial

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Statins may protect SCD children from pneumococcal infection

Statins may protect SCD children from pneumococcal infection

New research may yield more effective treatment for childhood leukemia

New research may yield more effective treatment for childhood leukemia

GSK receives European CHMP positive opinion for Revolade

GSK receives European CHMP positive opinion for Revolade

Retrospective study demonstrates new survival data for patients with myelofibrosis

Retrospective study demonstrates new survival data for patients with myelofibrosis

Statewide blood screening program identifies infants with T-cell lymphopenia

Statewide blood screening program identifies infants with T-cell lymphopenia

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

New genetic approach may hold promise for sickle cell disease

New genetic approach may hold promise for sickle cell disease